261 related articles for article (PubMed ID: 27431344)
1. Use of Biologics in Sjögren's Syndrome.
Nocturne G; Cornec D; Seror R; Mariette X
Rheum Dis Clin North Am; 2016 Aug; 42(3):407-17. PubMed ID: 27431344
[TBL] [Abstract][Full Text] [Related]
2. Emerging drugs for primary Sjögren's syndrome.
Gandolfo S; De Vita S
Expert Opin Emerg Drugs; 2019 Jun; 24(2):121-132. PubMed ID: 31286787
[No Abstract] [Full Text] [Related]
3. SER recommendations on the use of biological drugs in primary Sjögren's syndrome.
Andréu Sánchez JL; Fernández Castro M; Del Campo Fontecha PD; Corominas H; Narváez García FJ; Gómez de Salazar JR; Rua-Figueroa Í; Abad Hernández MÁ; Álvarez Rivas MN; Montes JDP; Francisco Hernández FM; Gantes Pedraza MÁ; Greco Merino MG; Hernández MV; Navarro Compán MV; Solarte JAP; Romero Bueno FI; Park HS; Sivera Mascaró F
Reumatol Clin (Engl Ed); 2019; 15(6):315-326. PubMed ID: 30683506
[TBL] [Abstract][Full Text] [Related]
4. New biological therapies in Sjögren's syndrome.
Nocturne G; Cornec D; Seror R; Mariette X
Best Pract Res Clin Rheumatol; 2015 Dec; 29(6):783-93. PubMed ID: 27107513
[TBL] [Abstract][Full Text] [Related]
5. Primary Sjogren's syndrome: current and prospective therapies.
Thanou-Stavraki A; James JA
Semin Arthritis Rheum; 2008 Apr; 37(5):273-92. PubMed ID: 17714766
[TBL] [Abstract][Full Text] [Related]
6. Biologics in Sjögren's syndrome.
Skarlis C; Marketos N; Mavragani CP
Pharmacol Res; 2019 Sep; 147():104389. PubMed ID: 31415917
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of biological DMARDs modulating B cells in primary Sjögren's syndrome: Systematic review and meta-analysis.
Letaief H; Lukas C; Barnetche T; Gaujoux-Viala C; Combe B; Morel J
Joint Bone Spine; 2018 Jan; 85(1):15-22. PubMed ID: 28673789
[TBL] [Abstract][Full Text] [Related]
8. Biologic treatments in Sjögren's syndrome.
Bowman S; Barone F
Presse Med; 2012 Sep; 41(9 Pt 2):e495-509. PubMed ID: 22836195
[TBL] [Abstract][Full Text] [Related]
9. Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.
Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Hatron PY; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Seror R; Pers JO; Meiners PM; Vissink A; Bootsma H; Nowak E; Saraux A
Rheumatology (Oxford); 2015 Sep; 54(9):1699-708. PubMed ID: 25957440
[TBL] [Abstract][Full Text] [Related]
10. Biologics in oral medicine: Sjogren syndrome.
O'Neill ID; Scully C
Oral Dis; 2013 Mar; 19(2):121-7. PubMed ID: 22497865
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Sjögren's syndrome: current therapy and future directions.
Fox RI; Fox CM; Gottenberg JE; Dörner T
Rheumatology (Oxford); 2021 May; 60(5):2066-2074. PubMed ID: 31034046
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.
De Vita S; Quartuccio L; Seror R; Salvin S; Ravaud P; Fabris M; Nocturne G; Gandolfo S; Isola M; Mariette X
Rheumatology (Oxford); 2015 Dec; 54(12):2249-56. PubMed ID: 26242856
[TBL] [Abstract][Full Text] [Related]
13. [Current therapeutic options in Sjögren's syndrome].
Hansen A; Dörner T
Z Rheumatol; 2010 Feb; 69(1):19-24. PubMed ID: 20013285
[TBL] [Abstract][Full Text] [Related]
14. Abatacept treatment of patients with primary Sjögren's syndrome results in a decrease of germinal centres in salivary gland tissue.
Haacke EA; van der Vegt B; Meiners PM; Vissink A; Spijkervet FK; Bootsma H; Kroese FG
Clin Exp Rheumatol; 2017; 35(2):317-320. PubMed ID: 27908305
[TBL] [Abstract][Full Text] [Related]
15. Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation.
Moutsopoulos NM; Katsifis GE; Angelov N; Leakan RA; Sankar V; Pillemer S; Wahl SM
Ann Rheum Dis; 2008 Oct; 67(10):1437-43. PubMed ID: 18198195
[TBL] [Abstract][Full Text] [Related]
16. Detailed Analysis of the Articular Domain in Patients with Primary Sjögren Syndrome.
Moerman RV; Arends S; Meiners PM; Vissink A; Spijkervet FK; Kroese FG; Brouwer E; Bootsma H
J Rheumatol; 2017 Mar; 44(3):292-296. PubMed ID: 28089983
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab for refractory organising pneumonia associated with Sjögren's disease.
Justet A; Ottaviani S; Dieudé P; Taillé C
BMJ Case Rep; 2015 May; 2015():. PubMed ID: 25976199
[TBL] [Abstract][Full Text] [Related]
18. Pyoderma gangrenosum in Sjögren's syndrome and its successful treatment with topical application of etanercept.
Haridas V; Shetty P; Dsouza LC; Dinesh US; Haridas K; Bargale A
Int J Rheum Dis; 2017 May; 20(5):657-659. PubMed ID: 28419761
[No Abstract] [Full Text] [Related]
19. The value of rituximab treatment in primary Sjögren's syndrome.
Verstappen GM; van Nimwegen JF; Vissink A; Kroese FGM; Bootsma H
Clin Immunol; 2017 Sep; 182():62-71. PubMed ID: 28478105
[TBL] [Abstract][Full Text] [Related]
20. Present and novel biologic drugs in primary Sjögren's syndrome.
Fasano S; Isenberg DA
Clin Exp Rheumatol; 2019; 37 Suppl 118(3):167-174. PubMed ID: 31025931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
